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Introduction: We have hypothesized that incompatibility between the G1m genotype of the patient and the
G1m1 and G1m17 allotypes carried by infliximab (INX) and adalimumab (ADM) could decrease the efficacy of
these anti-tumor necrosis factor (anti-TNF) antibodies in the treatment of rheumatoid arthritis (RA).
Methods: The G1m genotypes were analyzed in three collections of patients with RA totaling 1037 subjects.
The first, used for discovery, comprised 215 Spanish patients. The second and third were successively used for
replication. They included 429 British and Greek patients and 393 Spanish and British patients, respectively. Two
outcomes were considered: change in the Disease Activity Score in 28 joint (ΔDAS28) and the European League
Against Rheumatism (EULAR) response criteria.
Results: An association between less response to INX and incompatibility of the G1m1,17 allotype was found in the
discovery collection at 6 months of treatment (P = 0.03). This association was confirmed in the replications (P = 0.02
and 0.08, respectively) leading to a global association (P = 0.001) that involved a mean difference in ΔDAS28 of 0.4
units between compatible and incompatible patients (2.3 ± 1.5 in compatible patients vs. 1.9 ± 1.5 in incompatible
patients) and an increase in responders and decrease in non-responders according to the EULAR criteria (P = 0.03).
A similar association was suggested for patients treated with ADM in the discovery collection, but it was not
supported by replication.
Conclusions: Our results suggest that G1m1,17 allotypes are associated with response to INX and could aid
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Advances in the treatment of rheumatoid arthritis (RA)
including anti-tumor necrosis factor (anti-TNF) mono-
clonal antibodies have led to successful control of the
disease in many patients [1]. However, it is still necessary
to change the initial drug because of poor efficacy in a
significant fraction of them. This trial and error ap-
proach increases the burden of RA and could consume
the early months after RA onset when a better long-
term prognosis could be obtained [2]. Confronted with
this problem rheumatologists have sought predictive bio-
markers to orient drug choice [3,4]. A few have already
been found as autoantibody seronegativity that identifies
patients with poor response to rituximab, but more are
needed [3-6].
An area of recent progress has been awareness of the
importance of the blood levels of the biologics at the
trough between two treatment doses and of anti-drug
antibodies [7-13]. These antibodies could work in two
ways to decrease the drug’s efficacy: neutralizing the bio-
logic and increasing its clearance. They are present inFigure 1 Genomic structure and sequence of the G1m allotypes. In th
constant gamma 1 (IGHG1) gene in chromosome14 is shown with white re
sequence. Below, the IGHG1 sequences that were amplified to genotype rs
shown with the aligned sequences that could be co-amplified with the sam
IGHG2 and IGHG4 code for the heavy chains of IgG3, IgG2 and IgG4, respec
boxes. The three nsSNPs encoding the allotypes are in bold following the I
for the G/A alleles at rs1071803; M for the C/A alleles at rs11621259; and K f
allotype. Primers and minisequencing probes are underlined. nsSNP, non symost patients showing infusion reactions to infliximab
(INX) [12,14,15].
A related area of concern for biologics that bear the
fragment crystallizable (Fc) of immunoglobulin G (IgG)
is the possibility of inducing anti-allotype antibodies or
T cell reactions in incompatible patients [16-20]. The al-
lotypes are protein polymorphisms in the IgGs that are
able to induce antibodies when injected in incompatible
subjects (those not bearing them). There are several hu-
man immunoglobulin allotypes, but for the biologics used
to treat RA the most relevant are in the heavy chain of
IgG1 (Figure 1). INX and adalimumab (ADM), two of the
most commonly used anti-TNF monoclonal antibodies,
bear the G1m1 and G1m17 allotypes [16,17]. At a genetic
level, these two allotypes are in perfect linkage disequilib-
rium (LD) in Europeans (r2 = 1) and, therefore, are re-
ferred as the G1m1,17 allotype but the anti-allotype
antibodies are directed either against the G1m1 epitope or
against the G1m17 epitope [21]. These allotypes are miss-
ing in a large fraction of Europeans, who are susceptible
to mounting an anti-allotype response when exposed toe upper graph, the schematic structure of the immunoglobulin heavy
ctangles for the CH exons and a black rectangle for the hinge (H)
1071803 (for G1m17/G1m3) and rs11621259 (for G1m1/nullG1m1) are
e primers according to Blastn (megablast, default settings). IGHG3,
tively, while IGHGP is a pseudogene. Exon sequences are framed in
nternational Union of Pure and Applied Chemistry nomenclature: R
or the G/T alleles at the other nsSNP encoding the G1m1/nullG1m1
nonymous single nucleotide polymorphisms.
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targeting biologics has been rare, but this could be due to
the technical challenges presented by these antibodies
[16,17,19,22]. In addition, exposition to the G1m1 allotype
in incompatible subjects induces T-cell responses di-
rected against a different peptide in the IgG1 molecule
[18]. The G1m1,17 allotypes could also influence treat-
ment response by modifying the strength of antibody
immune responses, as has been shown for several anti-
gens, for rheumatoid factor (RF), and for anti-ADM
antibodies [20,23-25]. These differences could be medi-
ated by the allotypes themselves or by other variants in
the immunoglobulin heavy chain locus (IGH) through
LD with the allotypes [26,27].
The IGH locus displays a high level of structural com-
plexity, with highly homologous genes (Figure 1) arising
from multiple segmental duplication events [26,27]. Conse-
quently, this locus is not adequately covered on genome-
wide SNP chips [23,28]. Specifically, none of the SNPs
coding for G1m allotypes or their tagging SNPs was in-
cluded in the genome-wide association studies (GWAS)
analyzing the response of patients with RA to treatment
with anti-TNF drugs [29-32].
Here, we show that incompatibility at the G1m allo-
type was associated with less response to treatment with
INX. This association was supported by three sets of pa-
tient samples, one used for discovery and the other two
for replication. The difference between G1m compatible
and incompatible patients was small, but of possible
utility because it is similar to that observed between
seronegative and seropositive patients in the response toFigure 2 Diagram representing the three rheumatoid arthritis patientrituximab, which is used in clinical practice, and because
it was stronger in some patient subgroups. A similar as-
sociation was found for the patients treated with ADM
in the discovery set, but it was not reproduced in the
first replication set, which included a considerably larger
number of ADM treated patients.
Methods
Patients
The three sets of patients with RA included in the study
are shown in Figure 2. The discovery set included 215
patients of Spanish ancestry with RA who were recruited
in six Spanish hospitals. Evaluations included the disease
activity score in 28 joints (DAS28), which was available
at the start of treatment with INX or ADM and after
three, six and twelve months. The first replication set
consisted of 429 patients treated with INX or ADM, 384
from the Biologics in Rheumatoid Arthritis Genetics and
Genomics Study Syndicate (BRAGGSS), all of them with
UK white ancestry, and 45 patients from two Greek hospi-
tals, all of them of Greek ancestry (Figure 2). The DAS28
of these patients was evaluated at the start and after six
months of treatment with INX or ADM. The second rep-
lication set of 393 patients with RA, all treated with INX,
was subsequently collected in twelve Spanish hospitals
(nine new hospitals plus new patients from three of the
hospitals contributing to the discovery set, n = 234
Spanish with white ancestry) and by BRAGGSS (n = 159
UK whites). Analyses were limited to the patients with
valid genotypes (95.3, 94.2 and 98.2% in the three pa-
tient sets, respectively): 205 from the discovery set (183sets and their composition.
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follow-up and 150 with twelve months follow-up); 404
from the first replication set (all with six month follow-
up); and 386 from the second replication set (97 with
three months of follow-up, 362 with six months of
follow-up and 169 with twelve months of follow-up). All
were biologic-naïve at treatment start. The indication of
treatment, choice of drug and control of evolution were
performed independently of this study. All patients pro-
vided their written informed consent. Collection of sam-
ples was approved by the local ethics committees (listed
in the Appendix) and the study was approved by the
Comité Ético de Investigación Clínica de Galicia (regis-
try numbers 2009/173, 2011/162 and 2013/156).
G1m allotype genotyping
The G1m allotypes were studied at the DNA level [17,18].
We have genotyped two nsSNPs encoding them: rs1071803
(which A allele codes for the G1m17 allotype, whereas
the G allele codes for the G1m3 allotype) and rs11621259
(which C allele codes for one of the two amino-acids com-
prising the G1m1 allotype, whereas the A allele codes for a
protein that does not induce antibodies, namely a null
allotype). Due to paralog sequences in other IGH genes,
there are no tests able to discriminate with confidence be-
tween G/A and A/A genotypes at rs1071803 and between
C/A and C/C genotypes at rs11621259 (Figure 1). A carrier
analysis was therefore performed that distinguished car-
riers and non-carriers of the G1m1,17 allotypes. Genotypes
were obtained by PCR amplification followed by single-
base extension with the SNaPshot Multiplex Kit (Applied
Biosystems, Foster City, California). Samples with different
genotypes were sequenced to assess the accuracy of results.
The primers used are listed in Additional file 1: Table S1.
Statistical analysis
The Statistica 7.0 (Statsoft) software was used through-
out. Appropriate analyses were performed to evaluate
differences in clinical characteristics stratified according
to the specific anti-TNF (Table 1). Thus, 2 × 2 tables
with Chi-square tests were used for comparing dichotom-
ous clinical characteristics, 2 × 3 tables for variables with
three levels as the EULAR response criteria, while t-tests
were used to evaluate differences between quantitative
clinical characteristics as ΔDAS28, baseline C-reactive
protein (CRP) or baseline erythrocyte sedimentation rate
(ESR). Response to treatment was considered as ΔDAS28
or according to the EULAR criteria [33]. A generalized
linear model for ΔDAS28 and a logistic regression model
for the EULAR criteria (confronting good responders with
non-responders; moderate responders were not consid-
ered) were fitted. Unadjusted and adjusted analyses were
conducted. Included covariates are indicated in each ana-
lysis. Samples with missing data for any of the variablesimplicated in each specific analysis were excluded.
Meta-analysis of the beta coefficients corresponding to
the regression models for the three sets of patients was
done according to a fixed effects model using inverse-
variance weights as implemented in the meta library of
the R project [34].
Results
Association in the discovery patient set
Patients with RA in the discovery collection showed a me-
dian of six years between diagnosis and start of the treat-
ment with INX or ADM (Table 1). They had clinical
characteristics of severe disease: 85.3% were seropositive,
84.9% had developed joint erosions and they had an active
disease (baseline DAS28 = 5.9 ± 1.2) after treatment with
a mean of 2.5 disease-modifying antirheumatic drugs
(DMARDs). The assessed treatment was with the first
biologic administered and it was most often INX (73.7%).
The patients treated with INX showed a lower decrease in
DAS28 at three and six months than the patients treated
with ADM, indicating the need to consider the drug as an
important variable in subsequent analyses. There were no
other significant differences between the patients treated
with the two anti-TNF drugs.
Results of the two nsSNPs for the G1m1,17 allotypes
were fully concordant confirming the perfect LD between
them. Slightly less than half the patients (49.3%) did not
carry the G1m1,17 allotypes and, therefore, were incom-
patible with the INX and ADM allotypes. A significant as-
sociation was found in unadjusted analysis between lower
response (ΔDAS28) and incompatibility at the G1m1,17
allotypes after six months of treatment (Table 2). This as-
sociation remained significant after adjusting for gender,
baseline DAS28, rheumatoid factor (RF) and anti-TNF
(frequency data provided in Additional file 1: Table S2).
Stratified analysis by anti-TNF showed significant associ-
ation in the two strata, but only with INX in the adjusted
analysis (Table 2). Association in patients treated with
ADM was dubious because it disappeared after adjusting
for the covariates, but the effect size was equal to that
shown in patients treated with INX (Beta = 0.16). There-
fore, the lack of association could be attributed to the
lower number of patients treated with ADM than with
INX and reduced statistical power (Table 2). No associ-
ation between ΔDAS28 and G1m1,17 carrier status was
found either at three or twelve months of treatment, but
nominal differences were in the same direction as that ob-
served at six months (data not shown). No significant as-
sociation was detected using the EULAR response criteria
at any time of follow-up (Additional file 1: Table S3).
First replication set
New patient samples from the UK and from Greece
were obtained to replicate the previous findings. These
Table 1 Clinical characteristics of the patients with rheumatoid arthritisa from the discovery collection
Features All patients Infliximab Adalimumab
Patients, number (%)a 205 151 (73.7) 54 (26.3)
Female (%) 83.4 85.4 77.8
Age at diagnosis, median (IQR) 47 (38 to 55) 47 (37 to 55) 48 (40 to 56)
Diagnosis to anti-TNF, median (IQR) 6 (3 to 12) 6 (3 to 12) 6 (2 to 11)
RF, % 74.5 74.7 74.1
ACPA, % 75.7 75.4 76.9
Erosive arthritis, % 84.9 83.5 88.9
Smoking, % 13.9 11.8 20.0
DMARDs before anti-TNF, mean ± SD 2.5 ± 1.2 2.5 ± 1.2 2.6 ± 1.1
Concomitant DMARDs (%) 97.5 98.0 96.3
Baseline ESR, median (IQR)b 34 (19 to 54) 34 (19 to 53) 34 (19 to 57)
Baseline CRP (mg/L), median (IQR)b 11.5 (5.5 to 23.9) 11.5 (5.5 to 23.9) 14.3 (5.5 to 23)
Baseline HAQ, median (IQR)b 1.5 (1.0 to 2.0) 1.5 (1.0 to 2.0) 1.4 (1.0 to 2.0)
DAS28, (mean ± SD)
baseline 5.9 ± 1.2 5.9 ± 1.1 5.9 ± 1.4
three months 3.9 ± 1.4 4.0 ± 1.5 3.5 ± 1.1
six months 3.8 ± 1.4 4.0 ± 1.5 3.4 ± 1.2
twelve months 3.7 ± 1.5 3.8 ± 1.5 3.4 ± 1.6
EULAR response, %
three months
responder 30.4 28.7 34.6
moderate 50.8 50.4 51.9
no-responder 18.8 20.9 13.5
six months
responder 32.8 32.1 34.8
moderate 43.5 40.7 52.2
no-responder 23.7 27.1 13.0
twelve months
responder 43.5 40.2 51.1
moderate 35.1 40.2 23.4
no-responder 21.4 19.6 25.5
aOnly patients with successful genotypes are included; bdata from <85% of patients: 157 for baseline ESR, 126 for baseline CRP and 171 for baseline HAQ. ACPA =
anti-cyclic citrullinated peptides; CRP = C-reactive protein; DAS28 = Disease Activity Score 28; DMARD = disease modifying anti-rheumatic drugs; ESR = erythrocyte
sedimentation rate; EULAR = European League Against Rheumatism; HAQ = Health Assessment Questionnaire; IQR = interquartile range; RF = rheumatoid factor;
SD = standard deviation.
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from the discovery set of patients in baseline DAS28, base-
line Health Assessment Questionnaire (HAQ), erosions,
time since disease diagnosis and smoking (Tables 1 and 3).
However, these patients also showed an established disease
(median of 10 years from diagnosis to the start of the first
anti-TNF treatment), showing high activity (baseline
DAS28 = 6.5 ± 1.1), frequent erosions (58.5%) and sero-
positivity (79.7%). There were some differences between
patients treated with INX and those treated with ADM
in this replication set: the INX treated patients were
younger at diagnosis, showed more joint erosions andresponded with less decrease in DAS28 than the pa-
tients treated with ADM. Therefore, it was also neces-
sary to consider the anti-TNF in the analysis.
More than half of the patients in this set (56.4%) were
carriers of the G1m1,17 allotypes. Non-carrier status
was associated with a lower response as evaluated with
ΔDAS28, but only in the patients treated with INX (n =
199; Table 4). The association was significant, both in
the unadjusted and in the adjusted analyses, replicating
the finding of the discovery set. No association was found
in the patients treated with ADM (Table 4). Analysis of
the secondary outcome, EULAR response criteria, also
Table 2 Association of incompatibility at G1m (G1m1,17- genotype) with less improvement in DAS28 at six months of
treatment with anti-TNF in the discovery samples
Unadjusted Adjustedb Adjustedb
G1m genotypea number Baseline DAS28 ΔDAS28 Beta P-value Beta P-value
All patients G1m1,17+ 92 5.9 ± 1.1 2.3 ± 1.6 0.20 0.006 0.14 0.02
G1m1,17- 94 5.7 ± 1.1 1.6 ± 1.5
INX G1m1,17+ 68 5.9 ± 1.1 2.1 ± 1.6 0.16 0.06 0.16 0.03
G1m1,17- 72 5.8 ± 1.1 1.6 ± 1.5
ADM G1m1,17+ 24 6.1 ± 1.3 2.9 ± 1.5 0.32 0.03 0.16 0.19
G1m1,17- 22 5.6 ± 1.4 1.9 ± 1.5
aCarrier status; banalyses adjusted for baseline DAS28, gender and RF (and anti-TNF for All patients). ADM, adalimumab; anti-TNF, anti-tumor necrosis factor;
DAS28, disease activity score in 28 joints; INX, infliximab; RF, rheumatoid factor.
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lotypes and worse response to INX (P = 0.03; Additional
file 1: Table S4), but not to ADM.
Second replication set
Subsequently, a new set of patients with RA treated with
INX was collected in Spanish hospitals and in the
BRAGGSS. These patients also showed active disease with
high baseline DAS28 (6.1 ± 1.2) and HAQ (1.9 (1.4 to
2.3)), a long evolution and common erosions (77.6%), but
with a lower frequency of seropositivity than the two pre-
vious patient sets (Table 3). Response to treatment at sixTable 3 Clinical characteristics of the patients with RA from t
First replication
Features All patients I
Patients, number (%) 404 1
Female (%) 77.2 7
Age at diagnosis, median (IQR) 46 (34 to 53) 4
Diagnosis to anti-TNF, median (IQR) 10 (5 to 17) 1
ACPA, %a 77.4 7
Erosive arthritis, %a 58.2 6
Smoking, %a 56.6 5
Concomitant DMARDs (%)a 100 1
Baseline HAQ, median (IQR) 2.0 (1.6 to 2.4) 2
DAS28, (mean ± SD)
baseline 6.5 ± 1.1 6
six months 4.1 ± 1.3 4
six months EULAR response, %
responder 21.3 1
moderate 69.6 7
no-responder 9.2 9
aData from <85% of patients: in the first replication (310 patients for concomitant D
ACPA; 115 patients for smoking). ACPA, anti-citrullinated peptide antibodies; ADM,
score in 28 joints; DMARDs, disease modifying antirheumatic drugs; EULAR, Europea
infliximab; IQR, interquartile range; RA, rheumatoid arthritis; SD, standard deviation.months was more similar to the discovery collection, with
more balanced proportions of the three response classes,
than to the first replication set.
Patients in this second replication set also showed an
association between lower response to treatment with
INX at six months and incompatibility at the G1m1,17
allotype (Table 4, lower rows), but the difference was
only significant before adjusting for covariates (P = 0.03,
versus P = 0.08 after adjustment by baseline DAS28 and
gender). Comparison of responder with non-responder
patients according to the EULAR criteria did not show
significant differences (Additional file 1: Table S4).he first and second replication collections
Second replication
nfliximab Adalimumab Infliximab
99 (49.3) 205 (50.7) 386
7.9 76.6 89.1
2 (33 to 51) 48 (36 to 56) 44 (35 to 51)
1 (6 to 18) 9 (4 to 17) 8 (4 to 15)
9.4 75.5 60.9
5.0 51.1 77.6
6.8 56.3 26.1
00 100 96.4
.0 (1.8 to 2.5) 2.0 (1.5 to 2.3) 1.9 (1.4 to 2.3)
.7 ± 1.0 6.3 ± 1.1 6.1 ± 1.2
.3 ± 1.3 3.8 ± 1.2 4.1 ± 1.5
7.1 25.4 29.2
3.4 65.9 46.9
.5 8.8 24.0
MARDs); in the second replication (196 patients for erosive arthritis; 174 for
adalimumab; anti-TNF, anti-tumor necrosis factor; DAS28, disease activity
n League against Rheumatism; HAQ, Health Assessment Questionnaire; INX,
Table 4 Association of G1m status with change in DAS28 at 6 months of treatment with anti-TNF
Unadjusted Adjustedb
First replication G1m genotypea number Baseline DAS28 ΔDAS28 Beta P-value Beta P-value
All patients G1m1,17+ 228 6.4 ± 1.1 2.5 ± 1.3 0.03 0.52 0.07 0.13
G1m1,17- 176 6.6 ± 1.1 2.4 ± 1.3
INX G1m1,17+ 116 6.7 ± 0.9 2.5 ± 1.2 0.14 0.04 0.15 0.02
G1m1,17- 83 6.8 ± 1.1 2.2 ± 1.3
ADM G1m1,17+ 112 6.1 ± 1.1 2.4 ± 1.3 −0.07 0.32 −0.01 0.83
G1m1,17- 93 6.4 ± 1.0 2.8 ± 1.3
Second replication
INX G1m1,17+ 203 6.2 ± 1.1 2.2 ± 1.5 0.11 0.03 0.08 0.08
G1m1,17- 159 6.1 ± 1.3 1.9 ± 1.5
aCarrier status; banalyses adjusted for baseline DAS28 and gender (and anti-TNF for All patients). ADM, adalimumab; DAS28, disease activity score in 28 joints;
IFX, infliximab.
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Results from the patients with RA in the three previous
sets were combined by simple pooling and by meta-
analysis. Pooled analysis showed a significantly worse re-
sponse at six months in the patients treated with INX who
were carriers of the incompatible allotypes (Table 5). Very
similar results were obtained by meta-analysis: significant
association between higher ΔDAS28 and G1m1,17 com-
patibility (Beta = 0.12, 95% confidence interval (C.I.) = 0.05
to 0.19, P = 0.0005) with no heterogeneity between the
three patient sets (I2 = 0%, 95% C.I. = 0.0 to 81.4%). In
addition, analysis according to the EULAR criteria showed
that the compatible patients were more commonly re-
sponders and less commonly non-responders to INX than
the incompatible patients (30.1% versus 21.5% responders
and 16.9% versus 22.4% non-responders; P = 0.03). On the
contrary, combined analysis of response to ADM at six
months (Table 5), or to any of the two anti-TNF at three
or twelve months (not shown) did not show significant
differences between G1m1,17 carriers and non-carriers.
Analysis of ΔDAS28 in function of the G1m1,17 status
was repeated adjusting for all characteristics that were
different between the discovery and replication setsTable 5 Combined analysis of G1m status according to chang
Strata G1m genotypea number Baseline DAS28 ΔDAS
All patients G1m1,17+ 523 6.3 ± 1.1 2.3 ± 1
G1m1,17- 429 6.2 ± 1.2 2.0 ± 1
INX G1m1,17+ 387 6.3 ± 1.1 2.3 ± 1
G1m1,17- 314 6.2 ± 1.3 1.9 ± 1
ADM G1m1,17+ 136 6.2 ± 1.1 2.5 ± 1
G1m1,17- 115 6.2 ± 1.2 2.5 ± 1
aCarrier status; banalyses adjusted for baseline DAS28 and gender (and anti-TNF for
adalimumab; DAS28, disease activity score in 28 joints; IFX, infliximab; NR, non-resp(baseline DAS28, gender, baseline HAQ, age at diagno-
sis, years from diagnosis to treatment, erosive arthritis,
anti-citrullinated peptide antibodies (ACPA) and smok-
ing; Additional file 1: Table S5). Results were very similar
to those already shown in spite of the exclusion of pa-
tients lacking data for any of the new covariates (Beta =
0.13, P = 0.01 for the 304 patients treated with INX who
had complete information). We also checked the effect
of stratification by the clinical characteristics taken indi-
vidually. There was a strong effect of the ACPA status.
A stronger association was observed in the ACPA negative
patients receiving INX (n = 132, Beta = 0.26, P = 0.00092)
than in the whole set of patients, whereas it was reduced
and non-significant in the ACPA positive subgroup (n =
342, Beta = 0.06, P = 0.19). In addition, stratification by
ACPA status of the patients receiving INX also showed
association at 12 months of follow-up in the ACPA
negative patients (n = 81, Beta = 0.22, P = 0.022 versus
n = 164, Beta = −0.08, P = 0.3 in the ACPA positive pa-
tients). No effect was found at three months. Also, the
association was stronger in the patients who initiated
treatment at a younger age than the median of the
whole set of patients (56 years) than in the group thate in DAS28 and to the EULAR criteria
28 Betab P-valueb Rc NRc ORb P-valueb
.4 0.09 0.002 153 (29.3) 79 (15.1) 1.5 0.035
.5 98 (22.8) 90 (21.0)
.5 0.11 0.001 116 (30.0) 67 (17.3) 1.5 0.03
.5 67 (21.3) 78 (24.8)
.4 0.03 0.55 37 (27.2) 12 (8.8) 1.1 0.57
.4 31 (27.0) 12 (10.4)
All patients); cnumber (% response class/all patients with this genotype). ADM,
onders; R, responders.
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0.000040 in the 369 patients starting INX at ≤56 years
versus Beta = −0.005, P = 0.9 in the 313 older patients)
and in those in whom treatment was delayed less since
diagnosis of RA (Beta = 0.20, P = 0.000054 in the 315 pa-
tients treated with INX ≤8 years after diagnosis, versus
Beta = 0.02, P = 0.7 in the 359 with >8 years of delay).
These two variables, age or treatment initiation and
delay since diagnosis were weakly correlated (r = 0.22),
and, consequently, the effect of one was not explained
by the effect of the other. In addition, we checked the
effect of considering the concomitant use of methotrex-
ate, which was the DMARD used by 85.1% of the 883
patients with this information. The results changed very
little, both when considering all the patients, or separ-
ately the patients treated with INX (n = 661, Beta = 0.11,
P = 0.0016). The association showed a trend to be stron-
ger in the patients taking methotrexate (Beta = 0.12),
but the low number of patients in the group not taking
this DMARD made the results inconclusive. Similarly,
no differences in the effect of the Gm1,17 allotype were
detected with the other clinical variables analyzed
(smoking habit, RF status and age at diagnosis).
Discussion
Our results showed a consistent association between the
G1m allotypes and response to treatment with INX at six
months of follow-up. A decreased ΔDAS28 was observed
in the patients with incompatible allotypes in the discov-
ery patients and in the two replication sets. In addition,
fewer responders and more non-responders were present
among the G1m1,17 incompatible patients than among
the compatible patients. The effect of G1m incompatibility
was weak in the whole set of patients, but stronger in
some patient subgroups. Therefore, we think that it could
be of clinical utility if it is confirmed in further studies.
We consider the association of response to INX as con-
sistently reproduced in spite of the P = 0.08 obtained in
the second replication, which is over the pre-specified sig-
nificance threshold. This opinion is supported by two ar-
guments. First, this study hypothesized a lower response
in the incompatible patients, which is the result that has
been found. Therefore, single-tailed tests could have been
used in place of two-tailed tests [35]. Single-tailed tests
would lead to more significant differences in the three pa-
tient sets including P = 0.04 in the second replication. Sec-
ond, some authors have recommended applying a lower
significance threshold for replication than for discovery to
compensate for the overestimated effect sizes commonly
obtained in the first study showing significant association
[36,37]. In any case, confirmation by independent re-
searchers is needed for validation of this biomarker.
Unfortunately, we cannot find support in the published
GWAS of response to anti-TNF because they did notinclude the allotype-specific nsSNPs and showed low
coverage of the IGH locus [23,28-32].
The requirement of replication is still more important
for the subgroup analyses that we only report here as hy-
pothesis generating exploratory results. This caution is
necessary because subgroup analyses are especially prone
to false positive results [38]. Therefore, the stronger asso-
ciations found in ACPA negative patients than in ACPA
positive patients, in patients younger than the median age
at treatment initiation and in those patients with a short
delay in treatment since diagnosis should be taken with
caution. These results, if confirmed, could reflect the
differences in immune responsiveness between the sub-
groups of patients.
In effect, our results are concordant with the initial hy-
pothesis involving induction of immune responses against
the incompatible allotype of INX. These immune re-
sponses could include anti-allotype antibodies [16,17,19]
or a T cell response independent of anti-allotype anti-
bodies [18]. The anti-allotype antibodies would target the
INX molecule leading to its accelerated clearance. Anti-
allotype antibodies have been found in polytransfused sub-
jects and in multiparous women [16] who were exposed
to blood containing allotype incompatible immunoglobu-
lins. However, these antibodies have not been found in
some studies that have searched for them after administra-
tion of IgG1-based drugs [17,20,39]. These negative results
have been attributed to the technical difficulty of the as-
says [16,17,19,22,39]. In this respect, the authors who were
successful in finding anti-allotype antibodies in patients
treated with IgG1-based drugs had used very sensitive as-
says, which included few washes to avoid dissociation of
low affinity antibodies and acid dissociation of pre-existing
immunocomplexes [19]. Our approach, at the DNA level
instead of the anti-allotype antibodies, has avoided these
technical difficulties, has permitted us to use patients
lacking sera at the relevant point in the treatment course,
and allows for other forms of involvement of the allotypes
beyond the induction of antibodies. One of these alterna-
tive mechanisms is a different type of immune response
against the G1m1 allotype that involves CD4 T cell activa-
tion and production of cytokines [18]. The T cell antigen
does not include the allotype but a nearby peptide that
becomes accessible to antigen processing and presentation
because the G1m1 allotype introduces an asparaginyl
endopeptidase cleavage site [18]. None of the two alterna-
tives, antibodies or T cell responses, could be tested in our
patients because of unavailability of the relevant samples.
Alternative mechanisms for the association that do not
involve anti-drug immune reactions could also be in-
voked. They are suggested by differences in the strength
of antibody responses against autoantigens, pathogens
and cancer antigens associated with the G1m allotypes
[20,23-25]. These associations could be due to the allotypes
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gamma receptors [40], or to other variants in the immuno-
globulin heavy chain locus that is very polymorphic,
displays extensive LD and includes the sequences of all im-
munoglobulin heavy chains [26,27].
The associations were observed in the three sets of
patients at six months with ΔDAS28, but only in the
first replication and in the combined analysis with the
EULAR response. This discordance between the out-
comes is congruent with the lower sensitivity to change
of the EULAR response, which was considered as a di-
chotomous variable, than of ΔDAS28, which is a con-
tinuous variable [41,42]. Another aspect of our study
deserving comment is that results at three or twelve
months of follow-up were non-significant (although the
same direction of change was observed). These negative
results could be ascribed to less powerful analysis due
to fewer patients with data available at these times than
at six months (Figure 2), or to latency in the develop-
ment of an immune response preventing association at
three months, or to change of treatment in patients show-
ing poor response at six months. In an attempt to com-
pensate by the latter confounding factor, we included the
33 patients that we knew had interrupted treatment after
six months due to inefficacy in the EULAR response ana-
lysis at twelve months (as non-responders), but this ana-
lysis did not show association (not shown). In addition, it
is possible that differences in the composition of the
patient sets at the different times of evaluation contribute
to the discrepant results. This alternative is suggested by
the demonstration of association at twelve months of
follow-up in the subset of ACPA negative patients, which
was also the subset with the strongest association at six
months of follow-up. At present, we cannot discriminate
between the discussed possibilities.
Differences between the discovery and the replication
sets included origin within Europe, baseline disease activ-
ity, time of evolution, seropositivity, erosions and smoking.
Reproducibility of the association across these differences
suggests that it is robust and that could be confirmed in
additional studies. This replication is a requirement before
defining the applicability of our findings. However, we can
already comment on the effect size of the INX association
we have observed. The mean difference in ΔDAS28
(which is larger than the attributable effect according to
linear regression analysis probably because it includes
effects attributable to other covariates) between G1m1,17
compatible and incompatible patients after six months in
INX was 0.4. This is below 0.6, the change considered sig-
nificant in the EULAR criteria [33] but similar to the dif-
ference in ΔDAS28 between seropositive and seronegative
RA patients treated with rituximab at six months (0.3 for
RF and 0.6 for ACPA according to a meta-analysis of pa-
tient registers [5]; and 0.35 for seropositive patients from ameta-analysis of clinical trials [6]), which is considered
sufficient to help in the choice of treatment. Therefore, it
is possible that the G1m1,17 allotypes could become use-
ful, after further confirmation and analysis, to inform drug
choice in RA treatment. This could be especially true in
some subgroups of patients as suggested by the strong as-
sociation in ACPA negative patients and in young patients
and those initiating treatment early.
In contrast with INX, patients treated with ADM did
not show consistent association between response and
G1m1,17 compatibility. The total number of ADM treated
patients was not enough to exclude with sufficient power
an effect as was observed with INX (643 patients will be
needed to exclude with 0.8 power an effect size of slope =
0.11). However, it is possible that G1m incompatibility
does not affect response to ADM because there is already
precedent of a study showing that response of RA patients
to ADM is not affected by their allotype [20]. In addition,
several differences between INX and ADM make more
likely the development of immune responses against the
first. They include the larger immunogenicity of other
parts of the INX molecule, which is a mouse/human
chimera, than of ADM, which is a human antibody; the
different routes of administration and much wider fluc-
tuations of INX than of ADM, and the development of
neutralizing anti-idiotypic antibodies against ADM that
could reflect the immunodominance of the ADM para-
tope over other epitopes [43]. The large fluctuations of
INX concentration are due to its intravenous adminis-
tration every eight weeks in contrast with the subcuta-
neous administration every two weeks of ADM [44].
Other biologics used for the treatment of RA bear the
G1m1 or G1m17 allotypes and it will be interesting to
study if the response to them is affected by the allotype
of the patients. Rituximab and tocilizumab bear the
G1m1,17 allotypes, whereas abatacept has the G1m1 al-
lotype and certolizumab pegol the G1m17 allotype due
to the incomplete presence of the IgG1 constant region
in their molecules [17,45-47]. Etanercept, in turn, can-
not induce any anti-allotype responses because it lacks
the G1m3/G1m17 allotypes and bears the null allotype
at G1m1 [46]. We were unable to find information about
the allotypes of golimumab (although, it is described as
bearing the INX IgG1 heavy chain [48]).
Conclusions
The G1m1,17 allotypes of patients with RA have shown
an association with response to INX treatment at six
months of follow-up. This association was replicated in
independent patient sets. The patients who were incom-
patible with the allotypes in the INX molecule showed a
poorer response than the compatible ones. This pattern
of response is consistent with the development of im-
mune reactivity against INX. The difference in response
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was small, but of possible utility because it was of similar
magnitude to the difference in response to rituximab be-
tween seronegative and seropositive patients, and be-
cause it was larger in some subgroups of patients.
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